JA
KDNY

JOYN Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

JOYN Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-269
Closed -$12K – 1896
2018
Q1 		$12K Buy
+269
New +$9.85K ﹤0.01% 754

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

JOYN Advisors's KDNY Position: Q2 2018 in Review

JOYN Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2018, closing a stake of 269 shares — an estimated $12K sold.

JOYN Advisors first reported a position in KDNY in Q1 2018 and held it in 1 quarter. The position peaked at $12K in Q1 2018. 89 funds tracked by Wall St. Rank hold KDNY as of Q2 2018.

  • JOYN Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • JOYN Advisors sold 269 Chinook Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $12K.
  • JOYN Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • JOYN Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $12K in Q1 2018.
  • 89 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2018.

Based on JOYN Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.